Hinge Health director funds sell stock near $93

Venture funds associated with a Hinge Health director disclosed early-September sales of HNGE Class A shares around $93 per share.

Rhea-AI Filing Summary

Hinge Health, Inc. (HNGE) director-affiliated funds reported open-market sales of the company’s Class A Common Stock in early September 2026. On September 2, Bessemer Venture Partners X L.P. sold 35,918 shares and Bessemer Venture Partners X Institutional L.P. sold 33,717 shares at a weighted average price of $93.01 per share, in multiple trades between $92.72 and $93.52.

On September 3, 2026, the same funds sold 516 and 484 shares, respectively, at a weighted average price of $92.64 per share, in trades between $92.05 and $92.99. Reporting person Robinson Elliott, a partner at Bessemer Venture Partners, has an indirect, passive economic interest and disclaims beneficial ownership beyond any pecuniary interest.

Insider Trade Summary

Sale: 0 shares

Sale 2 txns

Insider Robinson Elliott

Role Director

Sold 0 shs ($0.00)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2, F3	0	$0.00	$0.00
Sale	Class A Common Stock F1, F2	0	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 0 shares (Indirect, See footnote)

Footnotes (3)

1. F1. On September 2, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 35,918 and 33,717 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $93.01. These shares were sold in multiple transactions at prices ranging from $92.72 to $93.52. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
2. F2. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.
3. F3. On September 3, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 516 and 484 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.64. These shares were sold in multiple transactions at prices ranging from $92.05 to $92.99. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold by BVP X on September 2, 2026: 35,918 shares at $93.01 per share Shares sold by BVP X Inst on September 2, 2026: 33,717 shares at $93.01 per share Shares sold by BVP X on September 3, 2026: 516 shares at $92.64 per share +1 more

4 metrics

Shares sold by BVP X on September 2, 2026 35,918 shares at $93.01 per share Open-market sales of Hinge Health Class A Common Stock; trades $92.72–$93.52

Shares sold by BVP X Inst on September 2, 2026 33,717 shares at $93.01 per share Open-market sales of Hinge Health Class A Common Stock; trades $92.72–$93.52

Shares sold by BVP X on September 3, 2026 516 shares at $92.64 per share Open-market sales of Hinge Health Class A Common Stock; trades $92.05–$92.99

Shares sold by BVP X Inst on September 3, 2026 484 shares at $92.64 per share Open-market sales of Hinge Health Class A Common Stock; trades $92.05–$92.99

Key Terms

weighted average price, indirect, passive economic interest, beneficial ownership, pecuniary interest

4 terms

weighted average price financial

"sold 35,918 and 33,717 shares ... at a weighted average price of $93.01"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect, passive economic interest financial

"has an indirect, passive economic interest in the shares held"

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of the securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest, if any, in such securities"

FAQ

What insider activity did HNGE report in this Form 4?

The filing reports that Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P. sold HNGE Class A Common Stock in open-market transactions on September 2 and 3, 2026, at weighted average prices near $93 per share.

How many HNGE shares did the Bessemer funds sell and at what prices?

On September 2, BVP X sold 35,918 shares and BVP X Inst sold 33,717 shares at a weighted average price of $93.01. On September 3, they sold 516 and 484 shares, respectively, at a weighted average price of $92.64.

Over what price ranges were the HNGE shares sold by the Bessemer funds?

For the September 2 sales, prices ranged from $92.72 to $93.52. For the September 3 sales, prices ranged from $92.05 to $92.99. The weighted average prices were $93.01 and $92.64, respectively.

What is Robinson Elliott’s relationship to the HNGE shares sold?

Robinson Elliott is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares through interests in the Bessemer funds and their general partner. He disclaims beneficial ownership except to the extent of any pecuniary interest.

Were the reported HNGE trades made under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox as false and the footnotes do not mention any trading plan, so the reported transactions are not stated to have been made under a Rule 10b5-1 plan.

Does the Form 4 show how many HNGE shares the insider holds after these sales?

The non-derivative transaction rows list no post-transaction share balances for these indirect holdings, and the filing does not provide a specific total of HNGE shares held by the reporting person after the reported sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 06:14 PM Accepted by SEC EDGAR 09/04/2026 - 06:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson Elliott

(Last) (First) (Middle)

C/O BESSEMER VENTURE PARTNERS

1865 PALMER AVENUE, SUITE 104

(Street)

LARCHMONT NEW YORK 10538

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/02/2026		S		0(1)	D	$0	0	I	See footnote(1)(2)
Class A Common Stock	09/03/2026		S		0(1)	D	$0	0	I	See footnote(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 2, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 35,918 and 33,717 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $93.01. These shares were sold in multiple transactions at prices ranging from $92.72 to $93.52. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

3. On September 3, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 516 and 484 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.64. These shares were sold in multiple transactions at prices ranging from $92.05 to $92.99. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Augie Wilkinson, Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)